Granules India Announces Rs 2,000 Crore Capex Plan

Granules India has announced an organic capital expenditure plan of Rs 2,000 crore to be deployed over the next three to four years. The company is shifting its focus toward high-value, complex formulations away from traditional bulk generics like ibuprofen and paracetamol. Formulations currently account for approximately 75% of the company’s revenue.

Financial Position and Key Targets

The firm achieved a net cash surplus position following a Rs 1,093 crore promoter warrant conversion in mid-September 2026. A core part of the expansion involves its peptide Contract Development and Manufacturing Organization division, Ascelis Peptides.

• Rs 2,000 crore organic capital expenditure plan over the next three to four years.
• $50 million revenue run-rate target for Ascelis Peptides within three years.
• $100 million revenue target for the peptide division within five years.
• Rs 1,093 crore infusion from promoter warrant conversions in mid-September 2026.

The peptide division is supported by the Swiss subsidiary Senn Chemicals, which was acquired in 2025. Investment funds are earmarked for complex generics, oncology, peptide CDMO development, United States manufacturing, research and development, and quality digitalization.

Orient Cables Shareholding Overview

In separate corporate developments, Orient Cables India Ltd released its shareholding pattern details. The data outlines the percentage of equity held by company promoters alongside public shareholder distribution and other categories.

• Promoter holding breakdown detailing equity concentration.
• Public shareholders distribution across retail and institutional categories.
• Institutional interest metrics provided for investor ownership analysis.

The shareholding overview serves as a key indicator for market participants tracking ownership concentration and institutional presence in the stock.